High frequency of HLA-B44 allelic losses in human solid tumors

被引:23
作者
Cabrera, T
Maleno, U
Lopez-Nevot, MA
Redondo, M
Fernandez, MA
Collado, A
Garrido, F
机构
[1] Univ Granada, Serv Analisis Clin, Hosp Virgen Nieves, Granada 18014, Spain
[2] Univ Granada, Unidad Invest, Hosp Virgen Nieves, Granada 18014, Spain
[3] Hosp Costa Sol, Dept Analisis Clin, Marbella, Spain
关键词
HLA; expression; tumor; LOH; HLA-B44;
D O I
10.1016/S0198-8859(03)00164-2
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Human leukocyte antigen (HLA) class I downregulation, a frequent phenomenon observed in a variety of human tumors, favors tumor immune escape from T-lymphocyte recognition. However, it is not known whether a particular HLA class I allele is lost more frequently than others. To address this question we analyzed HLA class I expression in tumor tissues derived from 300 patients diagnosed as having breast, colorectal, or laryngeal carcinomas. Cryostatic tumor sections and a broad panel of anti-HLA class 1 monoclonal antibodies were used. We found that the HLA-B44 allele was lost more frequently than other HLA class I alleles, and that the difference was not related with changes in HLA-B44 allele frequencies between patients and controls. In addition, we observed that 35176 of the HLA-B44 negative tumors presented HLA haplotype loss associated with loss of hetetozygosity. These tests were performed on DNA samples obtained from microdissected tumor tissues. The results seem to indicate that HLA class I allelic losses are not randomly distributed during tumor development but that some HLA class I alleles, and HLA-B44 in particular, are more frequently downregulated and may play an important role in immune escape mechanisms. Human Immunology (C) American Society for Histocompatibility and Immunogenetics, 2003. Published by Elsevier Inc.
引用
收藏
页码:941 / 950
页数:10
相关论文
共 48 条
[1]   HLA ANTIGENS IN A SAMPLE OF THE SPANISH POPULATION - COMMON FEATURES AMONG SPANIARDS, BASQUES, AND SARDINIANS [J].
ARNAIZVILLENA, A ;
DECORDOBA, SR ;
VELA, F ;
PASCUAL, JC ;
CERVERO, J ;
BOOTELLO, A .
HUMAN GENETICS, 1981, 58 (03) :344-348
[2]  
BODMER WF, 1993, ANN NY ACAD SCI, V690, P42
[3]   Specific HLA class I down-regulation is an early event in cervical dysplasia associated with clinical progression [J].
Bontkes, HJ ;
Walboomers, JMM ;
Meijer, CJLM ;
Helmerhorst, TJM ;
Stern, PL .
LANCET, 1998, 351 (9097) :187-188
[4]   Tumor antigens [J].
Boon, T ;
Old, LJ .
CURRENT OPINION IN IMMUNOLOGY, 1997, 9 (05) :681-683
[5]   Analysis of HLA expression in human tumor tissues [J].
Cabrera, T ;
López-Nevot, MA ;
Gaforio, JJ ;
Ruiz-Cabello, F ;
Garrido, F .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2003, 52 (01) :1-9
[6]   High frequency of altered HLA class I phenotypes in invasive breast carcinomas [J].
Cabrera, T ;
Fernandez, MA ;
Sierra, A ;
Garrido, A ;
Herruzo, A ;
Escobedo, A ;
Fabra, A ;
Garrido, F .
HUMAN IMMUNOLOGY, 1996, 50 (02) :127-134
[7]  
Chiari R, 1999, CANCER RES, V59, P5785
[8]   A human minor histocompatibility antigen specific for B cell acute lymphoblastic leukemia [J].
Dolstra, H ;
Fredrix, H ;
Maas, F ;
Coulie, PG ;
Brasseur, F ;
Mensink, E ;
Adema, GJ ;
de Witte, TM ;
Figdor, CG ;
van de Wiel-van Kemenade, E .
JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 189 (02) :301-308
[9]   THE ASSOCIATION OF AN HPV16 ONCOGENE VARIANT WITH HLA-B7 HAS IMPLICATIONS FOR VACCINE DESIGN IN CERVICAL-CANCER [J].
ELLIS, JRM ;
KEATING, PJ ;
BAIRD, J ;
HOUNSELL, EF ;
RENOUF, DV ;
ROWE, M ;
HOPKINS, D ;
DUGGANKEEN, MF ;
BARTHOLOMEW, JS ;
YOUNG, LS ;
STERN, PL .
NATURE MEDICINE, 1995, 1 (05) :464-470
[10]  
Fleischhauer K, 1996, INT J CANCER, V68, P622